Search

Your search keyword '"Torensma, Bart"' showing total 305 results
Start Over Author "Torensma, Bart"
305 results on '"Torensma, Bart"'

25. Algehele anesthesie

Author

Anaison, Clair, Torensma, Bart, Van Loo, Benedikt, editor, Hennink-Schadenberg, Simon, editor, and Ouwehand, Kirsten, editor

Published
2023
Full Text
View/download PDF

27. Relaxantia

Author

Torensma, Bart, Van Loo, Benedikt, editor, Hennink-Schadenberg, Simon, editor, and Ouwehand, Kirsten, editor

Published
2023
Full Text
View/download PDF

47. Duration of Antibiotic Treatment for Foot Osteomyelitis in People with Diabetes.

Author

Gramberg, Meryl Cinzía Tila Tamara, Torensma, Bart, van Asten, Suzanne, Sieswerda, Elske, Sabelis, Louise Willy Elizabeth, den Heijer, Martin, de Vries, Ralph, de Groot, Vincent, and Peters, Edgar Josephus Gerardus

Subjects
PEOPLE with diabetes, TREATMENT duration, QUALITY of life, CINAHL database, OSTEOMYELITIS
Abstract

Background: The optimal antimicrobial treatment duration for diabetes-related foot osteomyelitis (DFO) currently needs to be determined. We systematically reviewed the effects of short and long treatment durations on outcomes of DFO. Methods: We performed a systematic review searching Cochrane, CENTRAL, MEDLINE, Embase, and CINAHL Plus from inception up to 19 January 2024. Two independent reviewers screened the titles and abstracts of the studies. Studies comparing short (<6 weeks) and long (>6 weeks) treatment durations for DFO were included. The primary outcome was amputation; the secondary outcomes were remission, mortality, costs, quality of life, and adverse events. Risk of bias and GRADE were assessed. Results: We identified 2708 references, of which 2173 remained after removing duplicates. Two studies were included. Differences in methodology precluded a meta-analysis. The primary outcome, major amputation, was reported in one study, with a rate of 10% in both the intervention and comparison groups (p = 1.00), regardless of treatment duration. For the secondary outcome, remission rates, the first study reported 60% in the intervention group versus 70% in the comparison group (p = 0.50). In the second study, remission rates were 84% in the intervention group versus 78% in the comparison group (p = 0.55). Data for the outcomes mortality, costs, and quality of life were not available. Short treatment duration may lead to fewer adverse events. The risk of bias was assessed as low to moderate, and the level of evidence ranged from very low to moderate. Conclusions: Our findings suggest that for DFO, there is no difference between a shorter and more prolonged duration of antimicrobial treatment regarding amputation and remission, with potentially fewer adverse events with shorter treatment durations. However, the uncertainty stems from limited, heterogeneous studies and generally low-quality evidence marred by moderate biases, imprecision, and indirectness. More high-quality studies are needed to substantiate these findings. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results